Corporate News
|
|
MPLN/Geneuity contributes to FDA approval of the Panther(TM) System |
|
Thursday, 28 June 2012 14:52 |
|
MPLN, through it's Geneuity Clinical Research Services Division, participated in the instrument performance evaluations that contributed to the FDA approval of the Panther(TM) system for use with the APTIMA 2 Combo assay, particularly testing for the common sexually transmitted infections Chlamydia trachomatis andNeisseria gonorrhoeae. "It is a credit to the scores of talented and dedicated scientists and engineers who made it happen. We believe that PANTHER will continue that revolution by bringing the power of fully-automated, sample to result capabilities to low- and medium- volume labs.," said Carl Hull, Gene-Probe's chairman and chief executive officer. |
|
|
Thursday, 28 June 2012 12:19 |
 The 2012 MPLN Relay for Life team had an outstanding year! Thanks to the generosity of MPLN employees, family, and friends, as well as on-site fundraising at the Blount County Relay for Life, our team of 12 was able to raise $2098.54 for the American Cancer Society. The mission of MPLN – our dedication to “make a difference in patient care by delivering the best technologies and services in laboratory medicine” – goes hand-in-hand with the mission of the American Cancer Society to “prevent cancer, save lives, and diminish suffering from cancer, through research, education, advocacy, and service.” We look forward to participating in future Relay for Life events and further supporting the American Cancer Society! - Katy Large, 2012 team captain |
|
Dr. Nicholas Potter appointed to the medical advisory board of Epigenomics AG |
|
Monday, 11 June 2012 13:25 |
|
Dr. Nicholas T. Potter has been appointed to the Medical Advisory Board of Epigenomics AG, a molecular diagnostics company developing and commercializing tests for the screening and diagnosis of cancer. Their lead product Epi proColon 2.0, a blood-based test for the early detection of colorectal cancer (CRC) which is currently marketed in Europe and in development in the US, was recently used to support a pivotal clinical trial for CRC detection and will be submitted to the FDA for approval later this year. He is currently the Chief Scientific Officer and Director of Molecular Diagnostics at Molecular Pathology Laboratory Network, Inc., in Maryville TN. |
|
MPLN Offers Valuable Tests to Fight Breast Cancer Every Month |
|
Tuesday, 11 October 2011 09:06 |
|
In 2011, an estimated 230,480 new cases of invasive breast cancer will be diagnosed among women in the United States, and an estimated 57,650 cases of in situ breast cancer will be detected.
To educate the public about breast cancer and the best ways to fight it, October is recognized as Breast Cancer Awareness Month.
Focused on fighting breast cancer this month and everyday, MPLN offers a comprehensive test menu and a strategic testing approach to support physicians with patient care.
From screening, diagnosis and prognosis to treatment selection and monitoring, MPLN offers advanced, step-by-step testing to provide valuable laboratory information at every stage of the health management process.
For more information about targeted tests and services for breast cancer at MPLN, contact a tecnical service speciaist at 800.932.2943. |
|
Indigo provides on-line status for ordered tests |
|
Thursday, 01 September 2011 00:00 |
|
A pending list is now available on Indigo to allow you to check the status of a test. By clicking “Pending List” in the blue header field you are able to search by accessioning number, patient’s first name, patient’s last name, or test. The pending list can be sorted in alphabetical order much like the Reports/Manifest fields. If you have questions, please call a client service specialist at 800-932-2943. |
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 Next > End >>
|
|
Page 1 of 7 |
